Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Voiding diary (VD) is an important tool in the evaluation of children with voiding symptoms. Voiding frequency, maximal voided volume (MVV), average voided volume (AVV) and nocturnal volume (NV) can be extracted and are valuable in diagnosing and monitoring these disorders. Recently, ICCS has reduced the period of data recording on VD from 3 to 2 days.We hypothesized that one day voiding diary would be enough for guiding treatment.
Materials And Methods: Children with overactive bladder (OAB) and primary monosymptomatic enuresis (PMNE) were oriented to fulfill a 3-day VD. Data obtained from VD were evaluated for the first day (1dVD), the first two days (2dVD), and all 3 days (3dVD) and compared according to the MVV, AVV, frequency, NV and expected bladder capacity (EBC). The Friedman, Student's t test and the Fisher's exact was used. ANOVA was used for multiple comparisons. We also used Pearson correlation test.
Results: Ninety-eight children were included, 59 had PMNE and 30 OAB. Frequency, AVV and VN were similar regardless how many days the voiding episodes were recorded. Only MVV was higher by a mean of only 32 mL on 3dVD compared to 1dVD. A 1dVD has a sensitivity of 93,9% and a positive likelihood ratio of 2.2. As for the correlation of MVV and EBC it was observed that in 83% of children, MVV was lower than EBC. MVV corresponds to 67% and 69% of EBC in children with PMNE and OAB, respectively.
Conclusion: We believe that 1dVD is sufficient to assess these children. It has a high sensitivity and good correlation to 3dVD in evaluating these children. Bladder capacity in this population, evaluated by maximum voided volume, was close to 68% of that obtained by the EBC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881818 | PMC |
| http://dx.doi.org/10.1590/S1677-5538.IBJU.2022.0375 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.
Urology
September 2025
Sumitomo Pharma America, Inc., Marlborough, MA.
Objective: To demonstrate the impact of vibegron treatment in the phase 3 COURAGE trial (NCT03902080) on clinically meaningful response parameters in men with overactive bladder (OAB) receiving pharmacological therapy for benign prostatic hyperplasia (BPH) as measured by standard, validated patient-reported outcomes.
Methods: Men >45 years with OAB receiving pharmacotherapy for BPH were randomly assigned 1:1 to vibegron 75 mg or placebo for 24 weeks. Participants completed bladder diaries assessing changes in micturition frequency, nocturia, and urge urinary incontinence (UUI); International Prostate Symptom Score (IPSS); and OAB questionnaire (OAB-q).
Wearable Personal Uroflowmeter for Measuring Urine Leakage in Women with Incontinence: Feasibility Study.
Biosensors (Basel)
July 2025
Department of Mechanical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
This paper describes a novel wearable personal uroflowmeter and its use to log urine leakage episodes in women. Consisting of a miniature flow rate sensor attached under the urethral meatus, it recorded both urine flow rate and volume during activities of daily living. The sensor communicated with a determining unit incorporating a microcontroller and an inertial measurement unit worn at the waist, facilitating the post-hoc determination of which activities and changes in pose caused leakage.
View Article and Find Full Text PDFArtificial intelligence-based prediction of treatment failure and medication non-adherence in overactive bladder management.
BMC Urol
August 2025
Department of Urology, Faculty of Medicine, Mersin University, Ciftlikkoy Campus, Yenişehir, Mersin, 33343, Turkey.
Background: Overactive bladder management presents significant challenges, with treatment failures and medication non-adherence posing substantial barriers to patient outcomes. Early prediction of these challenges could enable timely interventions and treatment modifications.
Objectives: To develop and validate an artificial intelligence-based prediction model for early identification of treatment failure and medication non-adherence in overactive bladder patients, with specific focus on different pathological subgroups including diabetic neuropathy.
Sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction.
Curr Urol
July 2025
North Shore Urology Research Group, St Leonards, New South Wales, Australia.
Background: Limited published data exist regarding the utility of sacral neuromodulation (SNM) for neurogenic lower urinary tract dysfunction (NLUTD), consisting of only small case series, and, to our knowledge, no Australian data have been published. The aim of this study was to evaluate the clinical outcomes of SNM for treatment of NLUTD in Australian patients.
Methods: A retrospective analysis was conducted of patients who received a permanent SNM implant between December 2014 and March 2021.
Efficacy and Safety of Mirabegron and Tamsulosin Combination Therapy Compared to Tamsulosin Monotherapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Results of a Multicenter, Randomized, Double-Blind, Phase III Clinical Trial.
World J Mens Health
July 2025
Department of Urology, Dong-A University Hospital, Dong-A University School of Medical, Busan, Korea.
Purpose: This study aimed to evaluate the efficacy and safety of mirabegron and tamsulosin combination therapy compared to tamsulosin monotherapy in benign prostatic hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS).
Materials And Methods: This phase 3, randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of mirabegron/tamsulosin combination therapy versus tamsulosin monotherapy in men with LUTS. The trial, conducted across 25 centers from July 2021 to October 2023.